Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at trastuzumab to reduce circulating tumour cells from breast cancer (EORTC 90091-10093; Treat CTC)

Overview

Cancer types:

Breast cancer

Status:

Results

Phase:

Phase 2

Details

This trial was done to see if trastuzumab can lower the number of circulating tumour cells after other treatment for breast cancer. This means cancer cells that have broken away from the original cancer and gone into the bloodstream.

The women taking part had:

  • cancer with none or very few proteins (HER2 negative cancer)

  • already had surgery and chemotherapy

The trial was supported by Cancer Research UK. It was open for people to join between 2013 and 2016. The team published the results in 2018.

Recruitment start: 30 April 2013

Recruitment end: 17 October 2016

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Anthony Kong

Supported by

European Organisation for Research and Treatment of Cancer (EORTC)

NIHR Clinical Research Network: Cancer

Roche

Other information

There is more information about this trial on the clinicaltrials.gov website (NCT01548677):

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)

Last reviewed: 1 December 2023

CRUK internal database number: 12703

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.